Natco-Lupin USFDA approval for Eribulin Injection 2026

Approval adds a new US oncology product

Lupin Limited and Natco Pharma Limited said the United States Food and Drug Administration has approved Natco’s Abbreviated New Drug Application (ANDA) for Eribulin Mesylate Injection, 1 mg/2 mL (0.5 mg/mL) single-dose vials. The update was dated June 03, 2026, and issued from Mumbai, India, and Naples, Florida. The approval is tied to the alliance between Lupin and Natco, with Lupin positioned as the alliance and marketing partner referenced in other Natco filings. In regulatory terms, the approval allows the partners to supply a generic equivalent in a tightly regulated oncology market. For investors tracking Indian pharma exports, USFDA outcomes remain a key swing factor because they influence product flow, compliance risk perception, and facility utilization.

What exactly was approved

The product approved is Eribulin Mesylate Injection in a 1 mg/2 mL presentation at 0.5 mg/mL, supplied in single-dose vials. Natco’s filing notes it is bioequivalent to the reference listed drug Halaven Injection of Eisai, Inc. The statement positions the approval as an ANDA outcome, which is the pathway used to market a generic drug in the US by demonstrating bioequivalence to the RLD. The announcement does not disclose launch timing, pricing, or expected market share, and it does not provide revenue guidance. Still, an approval in sterile injectables typically attracts attention because the category requires consistent manufacturing quality and strong compliance controls.

Patient indications highlighted in the filing

The companies said Eribulin Mesylate Injection is indicated for adults with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for metastatic disease. It is also indicated for unresectable or metastatic liposarcoma in patients who have received a prior anthracycline-containing regimen. These indications matter for market context because they sit within oncology settings where prescribing is protocol-driven and tends to align with labelled indications. The announcement does not cite any label expansions beyond these uses. It also does not describe any patient access programme or distribution arrangement in the US.

Erdafitinib update: tentative approval in three strengths

In a separate regulatory disclosure carried by Press Trust of India, Natco said it has received tentative approval from the US health regulator for Erdafitinib in strengths of 3 mg, 4 mg, and 5 mg. Natco described Erdafitinib as a generic version of Janssen Biotech Inc’s Balversa. The company said the drug is indicated for adult patients with locally advanced unresectable or metastatic urothelial carcinoma harbouring susceptible FGFR3 genetic alterations. Tentative approval typically signals that the application has met review requirements but cannot convert into a final approval until certain conditions are cleared, such as exclusivity or patent-related blocks. Natco did not provide timelines for conversion to final approval.

USFDA inspections: Chennai facility received seven observations

Natco also disclosed inspection outcomes from its API operations. Its API manufacturing facility in Manali, Chennai underwent a USFDA inspection conducted from November 17 to November 21, resulting in seven observations recorded on Form 483. Natco said the observations are procedural in nature and expressed confidence in its ability to address them comprehensively. The disclosure does not provide the detailed text of the observations, nor does it specify a target date for closure. For compliance watchers, the key fact remains the count and classification as “procedural” as described by the company.

Mekaguda API site: one VAI observation and EIR issued

Natco informed that the USFDA inspected its API Division in Mekaguda, Hyderabad, India from June 9 to June 13, 2025. The company received one observation in Form 483, classified as “Voluntary Action Indicated” (VAI). Natco further said the USFDA issued the Establishment Inspection Report (EIR) for the Mekaguda API facility on July 24, 2025. The EIR issuance is often tracked because it signals the inspection has moved to a documented close-out stage. The company did not indicate any enforcement action linked to this site in the disclosure provided.

Other regulatory milestones referenced across updates

Beyond these filings, the compiled updates also referenced Natco’s CDSCO approval for its semaglutide injection, after which Natco Pharma Ltd shares rose up to 11%. The same thread stated the company planned to launch the product in March, but it did not specify the year in the excerpt provided. Separately, Natco said it received final approval from the US health regulator for its first supplemental abbreviated new drug application (sANDA) filed from its new drug formulations facility at Visakhapatnam, Andhra Pradesh. The filing described the sANDA as a prior approval supplement that enables Natco’s JNPC SEZ facility at Ramky Pharma City, Visakhapatnam as an alternate site for manufacture of an approved drug product for the US market, but it did not disclose the product name.

Snapshot table: key facts and dates disclosed

Market impact: approvals versus compliance signals

For Natco and Lupin, the Eribulin approval adds to the pipeline of US-facing products where execution depends not just on the application outcome but also on manufacturing readiness and ongoing compliance. The same set of updates includes both approvals and inspection observations, which is typical in pharma where commercial momentum and regulatory scrutiny often move in parallel. The only quantified market reaction cited in the provided text is Natco Pharma Ltd shares rising up to 11% following CDSCO approval for semaglutide injection. There is no stated stock move linked specifically to the Eribulin approval or the Erdafitinib tentative approval in the excerpts provided.

Why the Lupin-Natco pairing matters

The June 03, 2026 announcement explicitly frames the approval as involving Lupin and Natco as alliance partners, reinforcing a model where Natco files and manufactures while Lupin supports commercial execution in the US market. A separate Natco note in the provided text also said its marketing partner Lupin launched Lapatinib Tablets, 250 mg, in the US after Natco received final USFDA approval for that ANDA. Together, these updates show a continued cadence of filings, approvals, and launches connected to the partnership, although no sales or market-size numbers are disclosed here. For readers following Indian pharma, the thread to watch remains how quickly newly approved products convert into steady supply without facility-related disruptions.

Conclusion

Natco and Lupin’s USFDA approval for Eribulin Mesylate Injection on June 03, 2026 adds another oncology product to their US portfolio, while Natco’s tentative approval for Erdafitinib expands the cancer pipeline. At the same time, Natco has flagged procedural Form 483 observations at its Chennai API site and a completed inspection cycle with EIR issuance at its Mekaguda facility. The next concrete developments to track from the disclosures are remediation progress on the Chennai observations, any conversion of Erdafitinib from tentative to final approval, and further updates on launches or site additions such as the Visakhapatnam sANDA alternate manufacturing approval.